9 completed. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
Follow Secondary Hyperparathyroidism: new trials by email Literature Review of Secondary Hyperparathyroidism trials Research Report on Secondary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism [14C] SHR6508 Injection - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 5 | 2024-12-23 | 2026-03-23 |
| A Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508；Placebo - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 54 | 2022-03-10 | 2023-08-08 |
| Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects CTAP101 Capsules - Vitamin D Insufficiency, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO Health, Inc. | 67 | 2018-08-20 | 2019-09-30 |
| A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 Etelcalcetide, Placebo - Secondary Hyperparathyroidism | Phase 1 | Completed | Amgen | 33 | 2018-03-01 | 2020-02-10 |
| Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis KHK7580 - Secondary Hyperparathyroidism | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 13 | 2014-05-01 | 2015-03-05 |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease Cinacalcet - Chronic Kidney Disease, Hyperparathyroidism, Secondary | Phase 1 | Completed | Amgen | 14 | 2011-01-25 | 2020-06-17 |
| LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients LEO 27847 - Secondary Hyperparathyroidism | Phase 1 | Completed | LEO Pharma | 72 | 2010-06-01 | 2025-02-24 |
| Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects CTAP101 Capsules, CTAP101 Injection - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO IP Holdings II, Inc. | 28 | 2009-05-01 | 2014-09-30 |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) CTAP201 Injection, Doxercalciferol - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO IP Holdings II, Inc. | 24 | 2008-11-01 | 2014-09-29 |
Hyperparathyroidism, Secondary (9) · Renal Insufficiency, Chronic (4) · Hyperparathyroidism (2) · Kidney Diseases (2) · Kidney Failure, Chronic (2) · Parathyroid Diseases (2) · Renal Insufficiency (2)
Endocrine System Diseases (9) · Hyperparathyroidism (7) · Parathyroid Diseases (7) · Chronic Disease (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Kidney Diseases (2) · Renal Insufficiency (2)
1 alpha-hydroxyergocalciferol (1) · Cinacalcet (1) · etelcalcetide hydrochloride (1)
Amgen (2) · OPKO IP Holdings II, Inc. (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Kyowa Kirin Co., Ltd. (1) · LEO Pharma (1) · OPKO Health, Inc. (1)
United States (4) · China (3) · Germany (2) · Japan (1) · Poland (1) · United Kingdom (1)
Joel Melnick, MD (2) · Jeremy Mussallem (1)